Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LX 101

Next Previous
Drug Profile

LX 101

Alternative Names: 765-IGF-MTX; IGF-methotrexate conjugate - IGF Oncology; IGF-MTX; IGF/MTX; Insulin-like-growth-factor-methotrexate-conjugate; LX-101

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IGF Oncology
  • Developer IGF Oncology; Lirum Therapeutics; University of Chicago
  • Class Abortifacients; Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Drug conjugates; Eye disorder therapies; Glutamates; Growth factors; Heart failure therapies; Peptides; Pterins
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Graves ophthalmopathy
  • No development reported Solid tumours
  • Discontinued Myelodysplastic syndromes; Myeloid leukaemia

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 18 Jul 2025 Discontinued - Phase-I/II for Myelodysplastic syndromes (Late-stage disease, Second-line therapy or greater) in USA (IV), before July 2025 (Lirum Therapeutics pipeline, July 2025)
  • 18 Jul 2025 Discontinued - Phase-I/II for Myeloid leukaemia (Late-stage disease, Second-line therapy or greater) in USA (IV), before July 2025 (Lirum Therapeutics pipeline, July 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top